JP2015531396A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531396A5
JP2015531396A5 JP2015535741A JP2015535741A JP2015531396A5 JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5 JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
antibody
subject
mabp1
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531396A (ja
JP6750941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062899 external-priority patent/WO2014055541A1/en
Publication of JP2015531396A publication Critical patent/JP2015531396A/ja
Publication of JP2015531396A5 publication Critical patent/JP2015531396A5/ja
Application granted granted Critical
Publication of JP6750941B2 publication Critical patent/JP6750941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535741A 2012-10-04 2013-10-01 精神障害の治療 Active JP6750941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
US61/709,741 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020090717A Division JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療

Publications (3)

Publication Number Publication Date
JP2015531396A JP2015531396A (ja) 2015-11-02
JP2015531396A5 true JP2015531396A5 (OSRAM) 2016-11-17
JP6750941B2 JP6750941B2 (ja) 2020-09-02

Family

ID=50435375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015535741A Active JP6750941B2 (ja) 2012-10-04 2013-10-01 精神障害の治療
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Country Status (7)

Country Link
EP (1) EP2903643A4 (OSRAM)
JP (3) JP6750941B2 (OSRAM)
KR (1) KR20150064091A (OSRAM)
CN (1) CN104684581A (OSRAM)
AU (1) AU2013327498B2 (OSRAM)
CA (1) CA2886757C (OSRAM)
WO (1) WO2014055541A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159976A2 (en) 2010-06-18 2011-12-22 Xbiotech, Inc. Arthritis treatment
CN103153340A (zh) 2010-08-23 2013-06-12 埃克斯生物科技公司 对肿瘤疾病的治疗
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CN110382001A (zh) 2017-02-16 2019-10-25 埃克斯生物科技公司 化脓性汗腺炎的治疗
EP4615135A1 (en) 2022-11-04 2025-09-10 Panasonic Intellectual Property Corporation of America Terminal, base station, communication method, and integrated circuit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US8034337B2 (en) * 2008-05-30 2011-10-11 Xbiotech, Inc. Interleukin-1α antibodies
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
DK2694107T3 (en) * 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS

Similar Documents

Publication Publication Date Title
JP2015531396A5 (OSRAM)
JP2014509662A5 (OSRAM)
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
IL240179B (en) Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood
IN2014DN07149A (OSRAM)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
JP2015530399A5 (OSRAM)
HUE043355T2 (hu) LIV-1 elleni humanizált antitestek és alkalmazásuk a rák kezelésében
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
SG10201804945WA (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
BR112013002167A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
HUE046670T2 (hu) Anti IL-17RA ellenanyag kiszerelés és terápiás rendek pikkelysömör kezelésére
LT2013015A (lt) Farmacinės kompozicijos
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
JP2015524816A5 (OSRAM)
EP2703488A4 (en) COMPOSITION TO PREDICT SENSITIVITY TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS AND METHODS THEREFOR
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
WO2018111670A3 (en) Antibodies to human alpha-synuclein
JP2014526559A5 (OSRAM)
JP2015531397A5 (OSRAM)
RU2015110635A (ru) Лечение сосудистого заболевания и его осложнений
EP2991681A4 (en) TOPICAL COMPOSITION AND CARRIER FOR THE ADMINISTRATION OF PHARMACEUTICAL OR COSMETIC ACTIVE SUBSTANCES
WO2014185908A3 (en) Hybridoma clones, monoclonal antibodies, and methods of use